Stocks · News reference
8-K filing — INSULET CORP (PODD)
Filed: 2026-09-21 AccNo: 0001193125-26-396779 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
Insulet's Q2 Omnipod revenues grew 23.8% at constant currency with expanding global adoption, particularly for its Omnipod 5 automated insulin delivery system. The company raised 2026 international guidance and is progressing on next-generation products including Omnipod 6. However, intense competition, macroeconomic pressures, and supply chain risks could limit future margin expansion and profitability.
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.